Related Experiment Video
Updated: May 2, 2026

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization
Published on: September 15, 2018
Postmortem mRNA expression patterns in left ventricular myocardial tissues and their implications for forensic
Insights
Sudden cardiac death (SCD) diagnosis is improved by analyzing myocardial mRNA. Hemoglobin (HBA1/2, HBB) and pyruvate dehydrogenase kinase 4 (PDK4) mRNA levels serve as molecular signatures for fatal cardiac dysfunction.
Area of Science:
- Forensic Pathology
- Molecular Biology
- Cardiology
Background:
- Sudden cardiac death (SCD) is a leading cause of mortality in developed nations, often stemming from heart disorders.
- Diagnosing SCD postmortem can be challenging due to limited histological evidence.
- Myocardial ischemia, primarily from coronary artery disease, is a common cause of SCD.
Purpose of the Study:
- To identify distinct postmortem mRNA expression patterns in the heart for diagnosing SCD.
- To evaluate specific mRNA markers, including hemoglobin and pyruvate dehydrogenase kinase 4, for their utility in forensic investigations of cardiac death.
Main Methods:
- Analysis of postmortem mRNA expression levels of Hba1/2, Hbb, and Pdk4 in the left ventricular free wall.
- Comparison of mRNA expression between sudden cardiac death subjects and controls with non-cardiac causes of death.
- Correlation of mRNA expression with cardiac pathology, including acute myocardial infarction and ischemic heart disease.
Main Results:
- Hemoglobin A1/2 and B (Hba1/2, Hbb) mRNA levels were elevated in SCD cases compared to controls.
- Pyruvate dehydrogenase kinase 4 (Pdk4) mRNA levels were decreased in SCD subjects.
- These distinct mRNA expression patterns were observed even in cases without apparent pathological signs of heart injury.
Conclusions:
- Altered myocardial Hba1/2, Hbb, and Pdk4 mRNA expression patterns can serve as molecular signatures for fatal cardiac dysfunction.
- These molecular signatures can aid in forensically implicating SCD as the primary cause of death.
- The findings offer a novel approach to improve postmortem diagnosis in cases of suspected sudden cardiac death.
Abstract:
Sudden cardiac death (SCD), which is primarily caused by lethal heart disorders resulting in structural and arrhythmogenic abnormalities, is one of the prevalent modes of death in most developed countries. Myocardial ischemia, mainly due to coronary artery disease, is the most common type of heart disease leading to SCD. However, postmortem diagnosis of SCD is frequently complicated by obscure histological evidence. Here, we show that certain mRNA species, namely those encoding hemoglobin A1/2 and B (Hba1/2 and Hbb, respectively) as well as pyruvate dehydrogenase kinase 4 (Pdk4), exhibit distinct postmortem expression patterns in the left ventricular free wall of SCD subjects when compared with their expression patterns in the corresponding tissues from control subjects with non-cardiac causes of death. Hba1/2 and Hbb mRNA expression levels were higher in ischemic SCD cases with acute myocardial infarction or ischemic heart disease without recent infarction, and even in cardiac death subjects without apparent pathological signs of heart injuries, than control subjects. By contrast, Pdk4 mRNA was expressed at lower levels in SCD subjects. In conclusion, we found that altered myocardial Hba1/2, Hbb, and Pdk4 mRNA expression patterns can be employed as molecular signatures of fatal cardiac dysfunction to forensically implicate SCD as the primary cause of death.
More Related Videos
Related Concept Videos
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Myocarditis I: Introduction
Cardiomyopathy III: Hypertrophic Cardiomyopathy

